Iron overload disorders represent a variety of conditions that lead to increased total body
iron stores and resultant end‐organ damage. An elevated ferritin and transferrin‐iron …

Excess iron can be extremely toxic for the body and may cause organ damage in the
absence of iron chelation therapy. Preclinical studies on the role of free iron on bone marrow …

Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm that is mainly
characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia …

The classical Philadelphia chromosome–negative myeloproliferative neoplasms (MPN),
which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in …

Deferasirox (DFX) is used for the management of iron overload (IOL) in many
haematological malignancies including myelofibrosis (MF). The 'RUX‐IOL'study …

Myelofibrosis (MF) and myelodysplastic syndrome (MDS) are hematopoietic stem cell
disorders associated with cytopenias and red blood cell (RBC) transfusion dependence. Iron …

磁共振成像技术在铁过载诊断及随访中的应用- PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

At present, very few data are available on deferasirox (DFX) in the treatment of patients with
Philadelphia‐negative myeloproliferative neoplasms in fibrotic phase (FP‐MPN) and …

Ricchi, P., Ammirabile, M., Costantini, S., Di Matola, T., Verna, R., Diano, A., Foglia, MC,
Spasiano, A. & Cinque, P.(2012) A useful relationship between the presence of …